Immunological Heterogeneity of the RCC Microenvironment: Do Targeted Therapies Influence Immune Response?
Immunological Heterogeneity of the RCC Microenvironment: Do Targeted Therapies Influence Immune Response?
复制标题
DOI：
10.1007/s11912-012-0229-9
复制
发表时间：
2012-06-01
影响因子：
4.7
通讯作者：
Griffioen, Arjan W.
中科院分区：
文献类型：
--
作者：
Bex, Axel;Etto, Tamara;Griffioen, Arjan W.
靶向药物的引入大大改善了转移性透明细胞肾细胞癌（RCC）的治疗。然而，完全反应是罕见的，治疗是不能治愈的。此外，关于最新一代强效和选择性血管内皮生长因子受体（VEGFR）酪氨酸激酶抑制剂（TKI）的信息表明，疗效已达到平台期。最近的数据显示，靶向药物参与调节RCC的免疫反应。此外，目前的研究增加了我们对RCC如何逃避有效的抗肿瘤反应的理解，并有可能通过药物开发来调节这些过程。本文综述了靶向治疗引起的肾细胞癌免疫微环境的变化，总结了现有的证据，并讨论了潜在的治疗意义。
The introduction of targeted agents has substantially improved treatment of metastatic clear-cell renal cell carcinoma (RCC). However, complete responses are rare and therapy is not curative. Moreover, information on the latest generation of potent and selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) suggests that a plateau has been reached in terms of efficacy. Recent data reveal that targeted agents are involved in modulating immune responses in RCC. In addition, current research adds to our understanding of how RCC escapes an effective anti-tumor response with the potential to modulate these processes by drug development. This review provides specific insight into targeted therapy induced changes in the immunological microenvironment of RCC, summarizes the available evidence, and discusses potential therapeutic implications.